CN110339153A - 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用 - Google Patents
地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用 Download PDFInfo
- Publication number
- CN110339153A CN110339153A CN201910639315.3A CN201910639315A CN110339153A CN 110339153 A CN110339153 A CN 110339153A CN 201910639315 A CN201910639315 A CN 201910639315A CN 110339153 A CN110339153 A CN 110339153A
- Authority
- CN
- China
- Prior art keywords
- dexamethasone
- preparation
- days
- single unit
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title claims abstract description 128
- 229960003957 dexamethasone Drugs 0.000 title claims abstract description 121
- 239000002552 dosage form Substances 0.000 title claims abstract description 44
- 208000002177 Cataract Diseases 0.000 title claims abstract description 35
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 28
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 89
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000008188 pellet Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 206010053781 Anterior chamber cell Diseases 0.000 claims description 22
- 206010036346 Posterior capsule opacification Diseases 0.000 claims description 19
- 230000008595 infiltration Effects 0.000 claims description 18
- 238000001764 infiltration Methods 0.000 claims description 18
- 238000009938 salting Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 238000002627 tracheal intubation Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000002148 esters Chemical group 0.000 claims description 3
- 229940071643 prefilled syringe Drugs 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 244000248349 Citrus limon Species 0.000 claims 2
- 235000005979 Citrus limon Nutrition 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 3
- 239000003889 eye drop Substances 0.000 description 29
- 210000001508 eye Anatomy 0.000 description 25
- 229940012356 eye drops Drugs 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 210000002159 anterior chamber Anatomy 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 6
- 210000000695 crystalline len Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 206010054765 Anterior chamber inflammation Diseases 0.000 description 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 229960004875 difluprednate Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 229960003655 bromfenac Drugs 0.000 description 3
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 108010075600 citrate-binding transport protein Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- -1 Acyl triethyl citrate Chemical compound 0.000 description 2
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 238000011861 anti-inflammatory therapy Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960001798 loteprednol Drugs 0.000 description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- PESZCXUNMKAYME-UHFFFAOYSA-N Citroflex A-4 Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)C(C(C)=O)C(=O)OCCCC PESZCXUNMKAYME-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N carboxymethylsuccinic acid Natural products OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229940083224 ozurdex Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000013500 performance material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827091P | 2013-05-24 | 2013-05-24 | |
| US61/827,091 | 2013-05-24 | ||
| CN201480041856.1A CN105407896B (zh) | 2013-05-24 | 2014-05-23 | 缓释的地塞米松在白内障手术后的炎症中的应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480041856.1A Division CN105407896B (zh) | 2013-05-24 | 2014-05-23 | 缓释的地塞米松在白内障手术后的炎症中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110339153A true CN110339153A (zh) | 2019-10-18 |
Family
ID=51934201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910639315.3A Pending CN110339153A (zh) | 2013-05-24 | 2014-05-23 | 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用 |
| CN201480041856.1A Active CN105407896B (zh) | 2013-05-24 | 2014-05-23 | 缓释的地塞米松在白内障手术后的炎症中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480041856.1A Active CN105407896B (zh) | 2013-05-24 | 2014-05-23 | 缓释的地塞米松在白内障手术后的炎症中的应用 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10028965B2 (https=) |
| EP (2) | EP4082525A1 (https=) |
| JP (1) | JP6530744B2 (https=) |
| KR (1) | KR102245354B1 (https=) |
| CN (2) | CN110339153A (https=) |
| AU (1) | AU2014268434B2 (https=) |
| CA (1) | CA2913336C (https=) |
| ES (1) | ES2902951T3 (https=) |
| WO (1) | WO2014190248A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081808B1 (ko) | 2011-04-25 | 2020-02-26 | 아이콘 바이오사이언스, 인크. | 주사기용 투여량 가이드 |
| EP3302382A4 (en) | 2015-05-29 | 2019-02-20 | Allergan, Inc. | IMPLANT FOR THE TREATMENT OF OCULAR DISEASE |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| KR20190025635A (ko) | 2016-06-30 | 2019-03-11 | 듀렉트 코퍼레이션 | 데포 제형 |
| JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
| JP7394770B2 (ja) | 2018-02-09 | 2023-12-08 | アイコン バイオサイエンス，インコーポレイテッド | 注射器から少量の用量を装填および送達するためのシステム、キット、および方法 |
| WO2020168106A1 (en) | 2019-02-13 | 2020-08-20 | Notable Labs, Inc. | Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer |
| IT201900003529A1 (it) * | 2019-03-11 | 2020-09-11 | Ntc S R L | Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11974979B2 (en) | 2022-01-29 | 2024-05-07 | Resurge Therapeutics, Inc. | Treatments for benign prostatic hyperplasia |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060073182A1 (en) * | 2004-10-01 | 2006-04-06 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2013036309A2 (en) * | 2011-06-10 | 2013-03-14 | Wong Vernon G | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211793A (en) | 1979-03-19 | 1980-07-08 | American Cyanamid Company | Triethyl citrate solutions of PGE-type compounds |
| DE3500103C2 (de) | 1985-01-04 | 1987-01-22 | R.P. Scherer GmbH, 6930 Eberbach | Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff |
| US4889845A (en) | 1986-06-09 | 1989-12-26 | American Cyanamid Company | Vehicle for topical application of pharmaceuticals |
| AU5178193A (en) | 1992-11-09 | 1994-06-08 | Quest International B.V. | Solubilizing agents |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| US20030216303A1 (en) | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| WO2002000137A1 (en) | 2000-06-28 | 2002-01-03 | Shukla Atul J | Biodegradable vehicles and delivery systems of biologically active substances |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6960346B2 (en) | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| ITMI20032087A1 (it) | 2003-10-27 | 2005-04-28 | Pharmafilm S R L | Film autosupportanti per uso farmaceutico ed alimentare. |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| EP2266638A3 (de) | 2009-06-25 | 2014-08-13 | Biotronik VI Patent AG | Biokorrodierbares Implantat mit einer aktiven Beschichtung |
| US20110160645A1 (en) | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
| KR102081808B1 (ko) | 2011-04-25 | 2020-02-26 | 아이콘 바이오사이언스, 인크. | 주사기용 투여량 가이드 |
| US9289428B2 (en) | 2011-06-10 | 2016-03-22 | Ramscor, Inc. | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| ES2908977T3 (es) | 2013-06-03 | 2022-05-04 | Mcneil Ab | Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos |
-
2014
- 2014-05-23 ES ES14800446T patent/ES2902951T3/es active Active
- 2014-05-23 KR KR1020157036698A patent/KR102245354B1/ko active Active
- 2014-05-23 AU AU2014268434A patent/AU2014268434B2/en active Active
- 2014-05-23 CA CA2913336A patent/CA2913336C/en active Active
- 2014-05-23 EP EP21215082.5A patent/EP4082525A1/en not_active Withdrawn
- 2014-05-23 CN CN201910639315.3A patent/CN110339153A/zh active Pending
- 2014-05-23 EP EP14800446.8A patent/EP3003318B1/en active Active
- 2014-05-23 CN CN201480041856.1A patent/CN105407896B/zh active Active
- 2014-05-23 JP JP2016515111A patent/JP6530744B2/ja active Active
- 2014-05-23 US US14/893,381 patent/US10028965B2/en active Active
- 2014-05-23 WO PCT/US2014/039319 patent/WO2014190248A1/en not_active Ceased
-
2018
- 2018-06-26 US US16/018,931 patent/US10159683B2/en active Active
- 2018-12-10 US US16/215,579 patent/US20190105330A1/en not_active Abandoned
-
2022
- 2022-09-20 US US17/948,842 patent/US20230078906A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060073182A1 (en) * | 2004-10-01 | 2006-04-06 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2013036309A2 (en) * | 2011-06-10 | 2013-03-14 | Wong Vernon G | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Also Published As
| Publication number | Publication date |
|---|---|
| US10028965B2 (en) | 2018-07-24 |
| CN105407896B (zh) | 2019-08-27 |
| JP6530744B2 (ja) | 2019-06-12 |
| US20160120879A1 (en) | 2016-05-05 |
| WO2014190248A1 (en) | 2014-11-27 |
| EP3003318B1 (en) | 2021-12-22 |
| US20180303851A1 (en) | 2018-10-25 |
| KR20160040471A (ko) | 2016-04-14 |
| EP4082525A1 (en) | 2022-11-02 |
| EP3003318A1 (en) | 2016-04-13 |
| CN105407896A (zh) | 2016-03-16 |
| CA2913336C (en) | 2020-12-15 |
| KR102245354B1 (ko) | 2021-04-30 |
| CA2913336A1 (en) | 2014-11-27 |
| ES2902951T3 (es) | 2022-03-30 |
| US20190105330A1 (en) | 2019-04-11 |
| US20230078906A1 (en) | 2023-03-16 |
| US10159683B2 (en) | 2018-12-25 |
| AU2014268434A1 (en) | 2015-12-10 |
| EP3003318A4 (en) | 2017-01-04 |
| AU2014268434B2 (en) | 2018-11-22 |
| JP2016526039A (ja) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110339153A (zh) | 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用 | |
| Audren et al. | Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg | |
| Lindholm et al. | Perioperative subconjunctival triamcinolone acetonide injection for prevention of inflammation and macular oedema after cataract surgery | |
| US5888493A (en) | Ophthalmic aqueous gel formulation and related methods | |
| BR112021012492A2 (pt) | Composições farmacêuticas oftálmicas e métodos para tratar doença da superfície ocular | |
| Vasavada et al. | Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial | |
| JP2019167376A (ja) | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 | |
| CN109675038A (zh) | 增强低浓度阿托品类药物安全性和临床疗效的组合物 | |
| Stewart et al. | Intraocular pressure response to topically administered fluorometholone | |
| EP3787611B1 (en) | Liquid depot for non-invasive sustained delivery of agents to the eye | |
| CN105213418B (zh) | 一种眼科术前用复方滴眼液及其制备方法 | |
| CN103877005A (zh) | 一种复方奥氮平皮下埋植缓释剂 | |
| Kralinger et al. | Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study | |
| JP7358526B2 (ja) | 向上した眼の快適性を提供する組成物 | |
| JP2021523222A (ja) | 網膜への薬剤の持続送達のための点眼剤および方法 | |
| Alani | The ophthalmic rod: A new ophthalmic drug delivery system I | |
| CN102716108A (zh) | 一种布洛芬精氨酸氯化钠注射液及其制备方法和用途 | |
| HK40008204A (en) | Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation | |
| Jinapriya et al. | Anaesthetic plus dilating gel improves pupil dilation for cataract surgery | |
| CN104523575B (zh) | 一种盐酸羟苄唑眼用凝胶剂及其制备方法 | |
| Gayton | A clinical comparison of two different prednisolone acetate formulations in patients undergoing cataract surgery | |
| US20220323448A1 (en) | Compositions and methods for treating eyes and methods of preparation | |
| CA3061271A1 (en) | Bladder instillation composition with increased storage stability and containing chondroitin sulfate (4.5 mg/ml), hyaluronic acid (16 mg/ml) and phosphate buffer (ph 6.1 to 7.9), for the treatment of cystitis | |
| Reddy et al. | Comparative study of efficacy of topical dexamethasone 0.1% with difluprednate 0.05% in post-operative small incision cataract surgery | |
| CN100508987C (zh) | 玻璃酸在制备用于预防或改善眼玻璃体变性疾病的口服产品中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008204 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191018 |